The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Optimal sequencing of EGFR-targeted therapies for NSCLC
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the range of first-line EGFR-targeted therapies for non-small cell lung cancer (NSCLC). The FLAURA2 regimen (NCT04035486) of osimertinib plus chemotherapy has shown benefit in patients with aggressive disease, those with CNS metastasis, multiple metastases and ctDNA-positive disease, and brings the side effects associated with chemotherapy. The MARIPOSA regimen (NCT04487080) of amivantamab plus lazertinib produces the same benefit but also in patients with less aggressive disease, indicating a wider benefit. The sequencing of these regimens remains a challenge, and requires further data in order to decide the optimal sequence. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
